» Articles » PMID: 29393351

Preliminary Study of MicroRNA-126 As a Novel Therapeutic Target for Primary Hypertension

Overview
Journal Int J Mol Med
Specialty Genetics
Date 2018 Feb 3
PMID 29393351
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

The present study aimed to explore microRNA-126 (miR-126) as a novel therapeutic target for primary hypertension. The lentiviral vector containing human immunodeficiency virus 1 (HIV‑1), the miR‑126 gene knockdown viral vector (lenti-miR-126-KD), and control lentiviral vector (lenti‑scramble‑miR) were constructed. Spontaneously hypertensive rats were randomly divided into 4 groups, which received a high dose of lenti‑miR‑126‑KD (1x108, n=5), low dose of lenti‑miR‑126‑KD (1x107, n=6), scramble‑miR (5x107, n=6), and PBS (n=6). Lentiviral vectors were injected into the tail vein. Data on the systolic blood pressure, diastolic pressure, mean arterial pressure, and heart rate were collected weekly. After 8 weeks of virus administration, the distribution of lentiviral vectors in different tissues was observed by fluorescence microscopy. Picric acid Sirius red and H&E staining were used to observe the target organ damage, and the ELISA kit was used to determine the serum nitric oxide (NO) content. The lentiviral vector was found to be constructed successfully. Eight weeks after the lentiviral vector injection, green fluorescent protein was observed in different tissues in each group. The blood pressure and heart rate were not significantly altered after lentiviral vector injection (P>0.05). No significant differences in the heart‑to‑body weight ratio among the four groups were observed (P=0.23). Picric acid Sirius red and H&E staining revealed that there was no significant difference in morphology among the four groups. No significant difference in the serum NO level among the four groups was noted (P=0.23). The miR‑126 gene knockdown lentiviral vector was constructed successfully. No significant antihypertensive effect was observed by the knockdown of miR‑126 for the treatment of primary hypertension. The target organs were not protected significantly after the treatment. The increased level of miR‑126 expression in hypertensive patients may be due to a compensatory mechanism.

Citing Articles

Circulating MicroRNAs Related to Arterial Stiffness in Adults with HIV Infection.

Nanoudis S, Yavropoulou M, Tsachouridou O, Pikilidou M, Pilalas D, Kotsa K Viruses. 2025; 16(12.

PMID: 39772253 PMC: 11680088. DOI: 10.3390/v16121945.


A nested case-control study of circular ribonucleic acid expression profiles in the peripheral blood of pregnant women with pre-eclampsia.

Liao Q, Zheng L, Xu L, Jiang L, Luo J, Yan J Pak J Med Sci. 2024; 40(11):2658-2664.

PMID: 39634903 PMC: 11613381. DOI: 10.12669/pjms.40.11.10317.


Geriatric nutrition risk index in the prediction of all-cause and cardiovascular mortality in elderly hypertensive population: NHANES 1999-2016.

Huo X, Wu M, Gao D, Zhou Y, Han X, Lai W Front Cardiovasc Med. 2023; 10:1203130.

PMID: 37465450 PMC: 10350498. DOI: 10.3389/fcvm.2023.1203130.


Circulating Levels of MicroRNAs Associated With Hypertension: A Cross-Sectional Study in Male and Female South African Participants.

Matshazi D, Weale C, Erasmus R, Kengne A, Davids S, Raghubeer S Front Genet. 2021; 12:710438.

PMID: 34594360 PMC: 8476992. DOI: 10.3389/fgene.2021.710438.


Two novel microRNAs and their association with absolute blood pressure parameters in an urban South African community.

Matshazi D, Weale C, Erasmus R, Kengne A, Davids S, Raghubeer S Mol Biol Rep. 2021; 48(3):2553-2560.

PMID: 33759050 PMC: 8060202. DOI: 10.1007/s11033-021-06304-1.


References
1.
Wang F, Zheng Z, Guo J, Ding X . Correlation and quantitation of microRNA aberrant expression in tissues and sera from patients with breast tumor. Gynecol Oncol. 2010; 119(3):586-93. DOI: 10.1016/j.ygyno.2010.07.021. View

2.
Zhang J, Zhang Z, Zhang D, Zhu J, Zhang T, Wang C . microRNA 126 inhibits the transition of endothelial progenitor cells to mesenchymal cells via the PIK3R2-PI3K/Akt signalling pathway. PLoS One. 2013; 8(12):e83294. PMC: 3862723. DOI: 10.1371/journal.pone.0083294. View

3.
Lifton R, Gharavi A, Geller D . Molecular mechanisms of human hypertension. Cell. 2001; 104(4):545-56. DOI: 10.1016/s0092-8674(01)00241-0. View

4.
Gelinas D, Bernatchez P, Rollin S, Bazan N, Sirois M . Immediate and delayed VEGF-mediated NO synthesis in endothelial cells: role of PI3K, PKC and PLC pathways. Br J Pharmacol. 2002; 137(7):1021-30. PMC: 1573579. DOI: 10.1038/sj.bjp.0704956. View

5.
Fernandez-Real J, Vayreda M, Richart C, Gutierrez C, Broch M, Vendrell J . Circulating interleukin 6 levels, blood pressure, and insulin sensitivity in apparently healthy men and women. J Clin Endocrinol Metab. 2001; 86(3):1154-9. DOI: 10.1210/jcem.86.3.7305. View